Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
25 November 1997Website:
http://www.inotivco.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
NOTV Latest News
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:
Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.
Inotiv stock is experiencing a decline on Tuesday following the release of preliminary results for Q1 2024 by the drug discovery and development services company. The company has reported that its revenue for the six months ending on March 31, 2024 is expected to be $254.5 million.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
In the stock market, identifying the next big opportunity is like observing a celestial phenomenon. Today, through the cosmos of investment, three shining stars are identified for their potential for astronomical valuation possibilities.
Does Inotiv, Inc. (NOTV) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 1(current)
- 2
What type of business is Inotiv?
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
What sector is Inotiv in?
Inotiv is in the Healthcare sector
What industry is Inotiv in?
Inotiv is in the Diagnostics & Research industry
What country is Inotiv from?
Inotiv is headquartered in United States
When did Inotiv go public?
Inotiv initial public offering (IPO) was on 25 November 1997
What is Inotiv website?
https://www.inotivco.com
Is Inotiv in the S&P 500?
No, Inotiv is not included in the S&P 500 index
Is Inotiv in the NASDAQ 100?
No, Inotiv is not included in the NASDAQ 100 index
Is Inotiv in the Dow Jones?
No, Inotiv is not included in the Dow Jones index
When does Inotiv report earnings?
The next expected earnings date for Inotiv is 09 August 2024